Lexicon Pharma down 8% premarket on Q2 miss

Jul. 31, 2019 9:27 AM ETLexicon Pharmaceuticals, Inc. (LXRX)LXRXBy: Mamta Mayani, SA News Editor
  • Lexicon Pharmaceuticals (LXRX) Q2 results: Revenues: $9.7M (-29.7%); Net product revenue: $8.7M (+19.2%); Collaborative agreements: $0.9M (-85.9%); Royalties and other revenue: $0.2M (+150.0%).
  • Net Loss: ($23M) (+33.3%); Loss Per Share: ($0.22) (+33.3%); Quick Assets: $106M (-33.8%).
  • Anticipated Near-Term Milestones: September 2019 – Presentation of new analyses from studies of Zynquista in type 1 diabetes at the 55th Annual Meeting of the European Association for the Study of Diabetes.
  • 2H 2019 – Topline Phase 1b data for LX9211.
  • 2H 2019 – Topline results from core Phase 3 studies for Zynquista in type 2 diabetes.
  • 2H 2019 – Completion of patient enrollment of the initial safety cohort in the Phase 2 study of telotristat ethyl in biliary tract cancer.
  • Shares are down 8% premarket.
  • Previously: Lexicon Pharmaceuticals EPS misses by $0.16, misses on revenue (July 31)

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.